Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Siddharth Patel

Vascular Surgery Atlanta, GA Medical Doctor

NPI 1821001066 CMS profile 36860

980 Johnson Ferry Rd, Ste 1040, Atlanta, GA 30342

Open in the dashboard

General payments

$303,026

636 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$77,567 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Siddharth Patel of Atlanta, GA is reported in the CMS Open Payments database as having received $303,026 across 636 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $77,567 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,461 48
2024 General $52,756 74
2023 General $52,409 110
2022 General $48,850 114
2021 General $40,670 118
2020 General $22,820 48
2019 General $54,060 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Siddharth Patel
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Siddharth Patel were reported at $31,461. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Siddharth Patel Vascular Surgery median Middle half National median
2019 $54,060 $796 $226–$2,363 $163
2020 $22,820 $348 $118–$1,110 $114
2021 $40,670 $471 $158–$1,421 $132
2022 $48,850 $725 $222–$2,183 $149
2023 $52,409 $836 $257–$2,440 $160
2024 $52,756 $909 $252–$2,619 $164
2025 $31,461 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $244,606 343 payments
  2. Boston Scientific Corporation $31,193 45 payments
  3. Medtronic, Inc. $13,748 55 payments
  4. Shockwave Medical, Inc $3,324 55 payments
  5. Bolton Medical Inc $2,863 14 payments
  6. Inari Medical, Inc. $2,627 9 payments
  7. AngioDynamics, Inc. $632 14 payments
  8. W. L. Gore & Associates, Inc. $592 8 payments
  9. Abbott Laboratories $427 6 payments
  10. CVRx, Inc. $373 6 payments
  11. Other $2,641 81 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $162,018 49 payments
  2. Travel and Lodging $59,477 203 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $32,000 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $26,875 10 payments
  5. Food and Beverage $22,656 369 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Stent $171,554 215 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $171,554 215 payments
  3. ENROUTE 0.014 Guidewire $73,052 128 payments
  4. ENROUTE Transcarotid Stent System $73,052 128 payments
  5. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $73,052 128 payments
  6. ENHANCE Transcarotid Peripheral Access Kit Carotid Artery Disease $73,052 128 payments
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $50,915 43 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $50,915 43 payments
  9. ENHANCE Transcarotid Peripheral Access Kit Cardiology/Vascular Diseases $38,981 79 payments
  10. ENROUTE .014 Guidewire $38,981 79 payments
  11. Other $60,834 298 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

140

Median for Vascular Surgery: 122

Drug cost

$27,866

Median for Vascular Surgery: $14,135

Branded share of claims

91.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 45 $27,541
Clopidogrel Clopidogrel Bisulfate Brand 83 $308
Tramadol Hcl Generic 12 $17

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$156,168

Medicare's payments for the services billed

Medicare patients

725

Average age 76

Services billed

1,413

345 women, 380 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 52%
Diabetes 35%
Chronic kidney disease 33%
Atrial fibrillation 25%
Heart failure 23%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $14
$14 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

636 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record